Researchers developed three novel non-small cell lung cancer (NSCLC) patient-derived echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusion cell lines, including CUTO8 (variant 1), 9 (variant 1) and 29 (variant 3), as well as a fourth ALK-positive cell line, YU1077 (EML4-ALK variant 3).